Recon: Trump signs order to lower US drug prices; Lilly’s Zepbound beats Wegovy in weight loss study

• White House unveils sweeping plan to try to lower U.S. drug prices (STAT) (Reuters)
• First at-home test kit for cervical cancer approved by the FDA, company says (STAT)
• Beyond politics, even U.S. vaccine experts may envision fewer Covid shots in the future (STAT)
• Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial (Reuters)
• FDA, aiming to speed scientific reviews, names chief AI officer (MedTech Dive)

• Pharma stocks recover from initial shock of Trump's drug pricing order (Reuters)
• Bausch + Lomb receives CE mark for Luxlife intraocular lens (MedTech Dive)
• Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector (MedTech Insight)
• MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains (MedTech Insight)
• UK Medtech Strategy Promises To Use Innovation Effectively And Build Resilience (MedTech Insight)
• Will NICE’s New Medtech Evaluation Plans Hit the Target for Patients and Industry? (MedTech Insight)
• Bill Gates to accelerate spending at his foundation — then wind it down (STAT)

• Novartis to keep making malaria drugs if orders dry up amid aid cuts (Reuters)
• Roche boosts US presence with new $700 million North Carolina facility (Reuters)
• Exclusive: Patrick Hsu startup launches, looks beyond CRISPR for gene insertion technology (Endpoints)
• Vir’s hep B disappointment, Ipsen's new Iqirvo data, plus more from #EASL25 (Endpoints)
• FDA clears in vivo blood stem cell editing trial; Abeona's $155M PRV sale (Endpoints)
• AstraZeneca Loses Spot as UK’s Most Valuable Company to HSBC (Bloomberg)
• Pfizer partner touts HER2 ADC trial win in bladder cancer (Fierce Pharma)

• New Insulet CEO Ashley McEvoy sets priorities (MedTech Dive)
• SEC ends probe of Illumina’s Grail acquisition (MedTech Dive)
• ADA’s Osagie Ebekozien on diabetes tech for Type 2, new CGM standards (MedTech Dive)
• The Value Of Consumer Wearables Within The Clinic Is Currently Unknown, Says Cardiologist (MedTech Insight)

• FDA Approves Three Food Colors from Natural Sources (Food Safety) (FDA)
• FDA and NIH Announce Innovative Joint Nutrition Regulatory Science Program (FDA)

• Science is under attack. So I’m taking RFK Jr. to court (STAT)
• Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees to Pay $3.6M to Resolve Allegations that It Violated the False Claims Act in Connection with Marketing its Fentanyl Product (DOJ)
• House GOP unveils plans to reshape Medicaid (STAT)
• Chinese and Chinese-American researchers in the U.S. confront a perilous moment (STAT)
• Medicare Advantage challenges catch up to UnitedHealth (STAT)
• From pandemic preparedness to precious frozen spit, NIH contract terminations cut deep (STAT)
• Knock Knock. Who’s There? (or Quién es? or Qui est-ce? or Wer ist es?) Surprise, it’s FDA! (FDA Law Blog)